The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.
New York, NY (PRWEB) December 11, 2021 Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe